FDA Approves HERCEPTIN HYLECTA — Genentech, Inc.

Genentech, Inc. received FDA approval for Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) in early 2019, a formulation designed to significantly improve the convenience and speed of administering treatment for patients with HER2-positive breast cancer. The approval of this subcutaneous alternative to the traditional intravenous therapy is expected to enhance treatment adherence and broaden market accessibility for this widely used sub-niche.